SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
P/S ratio for SI-BONE, Inc. (SIBN)
P/S ratio as of 2023: 5.81
According to SI-BONE, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.81. At the end of 2022 the company had a P/S ratio of 4.37.
P/S ratio history for SI-BONE, Inc. from 2012 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 5.81 |
| 2022 | 4.37 |
| 2021 | 8.17 |
| 2020 | 11.84 |
| 2019 | 7.89 |
| 2018 | 6.00 |
| 2017 | 5.80 |
| 2016 | 7.38 |
| 2015 | 11.73 |
| 2014 | 1.34 |
| 2013 | 0.94 |
| 2012 | 1.03 |